Efficacy of Zoledronic Acid Treatment in Paget Disease of Bone
|Emine Kartal Baykan*, Sevki Cetinkalp, Gokhan Ozgen and Candeger YÄ±lmaz|
|Department of Endocrinology and Metabolism, Ege University Medical Faculty, Turkey|
|Corresponding Author :||Dr. Emine Kartal Baykan
Department of Endocrinology and Metabolism
Ege University Medical Faculty, Izmir, Turkey
E-mail: [email protected]
|Received April 29, 2014; Accepted June 24, 2014; Published June 29, 2014|
|Citation: Baykan EK, Cetinkalp S, Ozgen G, Yilmaz C (2014) Efficacy of Zoledronic Acid Treatment in Paget Disease of Bone. J Osteopor Phys Act 2:120. doi: 10.4172/2329-9509.1000120|
|Copyright: © 2014 Baykan EK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Purpose: Paget disease is a disease of bone of unknown etiology with increased bone turnover that results in defective bone microarchitecture and bone deformity. Bisphosphonates are used in symptomatic Paget disease of bone. Clinical trials have shown that zoledronic acid was more effective than other bisphosphonates in treatment of Paget disease.
Methods: In this study, we retrospectively reviewed the remission and relapse statuses of 12 patients with Paget disease of bone, who were seen as outpatients between October 2011 and October 2013. We evaluated alkaline phosphates, osteocalcin, deoxypyridinoline levels measured before and at 6th, 12th, 18th months of treatment.
Results: Pretreatment values for alkaline phosphates, deoxypyridinoline, osteocalcin were as follows; 473 ± 256 U/L, 14.99 ± 7.63 mmol/L, 21.09 ± 3.18 ng/ml and post-treatmen valus for alkaline phosphates, deoxypyridinoline, osteocalcin were as follows; 82 ± 13 U/L, 5.14 ± 1.11 mmol/L, 8.57 ± 4.31 ng/ml. Remission was achieved in all patients after treatment. The levels indicated remission continued at 12th and 18th months of treatment. There was statistically significant difference between pretreatment and post-treatment values. No statistically significant difference between the levels measured at 6th, 12th and 18th months of treatment was detected.
Conclusion: We recommend zoledronic acid in the first line treatment of Paget disease of bone in achieving and maintaining remission.